Kwan Lee, MD
Interventional Cardiology · Scottsdale, AZNPI 1417931965
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.0%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Medtronic at 26.1% of the total. Reporting peaked in 2019 at $3,396 and has fallen 81.5% since, to $630 in 2025. That places this record below the midpoint for interventional cardiology clinicians in AZ, where the typical reported total is $10,657.
Across 130 payments — averaging $88.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Edwards Lifesciences$2K
- Philips North America LLC$1K
- Corindus Inc.$1K
- Abiomed$946
- ZOLL Circulation Inc$697
- plus $2K from 17 others
Across 2 payments — averaging $22,155 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ortho-clinical Diagnostics, Inc.$41K
- Philips North America LLC$3K
What the payments were for
- Consulting fees$4504%
- Speaking & faculty fees$6756%
- Travel & lodging$4,17436%
- Food & beverage$6,20954%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 33 | $3,005 |
| Edwards Lifesciences | 17 | $1,857 |
| Philips North America LLC | 10 | $1,411 |
| Corindus Inc. | 5 | $1,183 |
| Abiomed | 14 | $946 |
| ZOLL Circulation Inc | 4 | $697 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $664 |
| Novartis | 17 | $430 |
| Heartflow, Inc. | 4 | $278 |
| Abbott | 2 | $176 |
| Boston Scientific | 1 | $125 |
| Amgen | 1 | $124 |
| Regeneron Healthcare Solutions, Inc. | 2 | $123 |
| W. L. Gore & Associates, Inc. | 1 | $118 |
| AstraZeneca | 2 | $103 |
| Boehringer Ingelheim | 2 | $97 |
| Biotronik Inc. | 1 | $53 |
| Angiodynamics, Inc. | 1 | $38 |
| Saranas, Inc. | 1 | $24 |
| Lantheus Medical Imaging, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $13 |
| Terumo Medical Corporation | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CorPath GRX$1,100
- RESOLUTE ONYX$1,050
- Edwards SAPIEN 3 Transcatheter Heart Valve$993
- IGT Device Undivided$824
- TherOx DS2 Console$697
- Catheter$697
- Downstream Cartridge$697
- Resolute$675
- Impella$453
- LifeVest$366
- LEQVIO$262
- ELCA$233
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$231
- PORTICO$161
- CoreValve Evolut$130
- Watchman$125
- Repatha$124
- CARDIOFORM Septal Occluder$118
- COREVALVE EVOLUT R$118
- PRALUENT$112
How this compares
$11,508 in reported general payments places this provider in the 50th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 39 | $40,559 |
| FarxigaDapagliflozin Propanediol | 47 | $35,716 |
| JardianceEmpagliflozin | 21 | $20,269 |
| Ezetimibe | 101 | $2,715 |
| ClopidogrelClopidogrel Bisulfate | 52 | $726 |
| Atorvastatin Calcium | 44 | $546 |
| Rosuvastatin Calcium | 37 | $498 |
| Metoprolol Succinate | 28 | $458 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 13 | $444 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 16 | $319 |
| Losartan Potassium | 38 | $316 |
| Spironolactone | 38 | $293 |
| Isosorbide Dinitrate | 12 | $272 |
| Lisinopril | 14 | $135 |
| Metoprolol Tartrate | 11 | $124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $103 | $35,71647 claims |
| Boehringer IngelheimJardiance | $97 | $20,26921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Scottsdale
- Taral PatelScottsdale$171K
- Rebecca ChesterScottsdale$113K
- Mayurkumar BhaktaScottsdale$63K
- Nassim HaddadScottsdale$53K
- Ankur GuptaScottsdale$28K
- Andrew CluckeyScottsdale$27K
- Mazen RoumiaScottsdale$24K
- Raviinder MannScottsdale$23K
- Paul SorajjaPhoenix$1.1M
- Hursh NaikAvondale$781K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.